Cargando…

Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study

BACKGROUND: Migraine preventive medications are used to reduce headache frequency, severity, and duration. In patients with chronic migraine (CM), reversion to episodic migraine (EM) is an important treatment goal. OBJECTIVE: To evaluate the effect of fremanezumab on the rate of reversion from CM to...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipton, Richard B., Cohen, Joshua M., Bibeau, Kristen, Galic, Maja, Seminerio, Michael J., Ramirez Campos, Verena, Halker Singh, Rashmi B., Ailani, Jessica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756262/
https://www.ncbi.nlm.nih.gov/pubmed/33179323
http://dx.doi.org/10.1111/head.13997
_version_ 1783626501587992576
author Lipton, Richard B.
Cohen, Joshua M.
Bibeau, Kristen
Galic, Maja
Seminerio, Michael J.
Ramirez Campos, Verena
Halker Singh, Rashmi B.
Ailani, Jessica
author_facet Lipton, Richard B.
Cohen, Joshua M.
Bibeau, Kristen
Galic, Maja
Seminerio, Michael J.
Ramirez Campos, Verena
Halker Singh, Rashmi B.
Ailani, Jessica
author_sort Lipton, Richard B.
collection PubMed
description BACKGROUND: Migraine preventive medications are used to reduce headache frequency, severity, and duration. In patients with chronic migraine (CM), reversion to episodic migraine (EM) is an important treatment goal. OBJECTIVE: To evaluate the effect of fremanezumab on the rate of reversion from CM to EM. METHODS: This phase 3, randomized, double‐blind, placebo‐controlled, parallel‐group trial included a 28‐day pretreatment period and a 3‐month treatment period. Patients with CM received subcutaneous fremanezumab quarterly (675 mg at baseline) or monthly (675 mg at baseline; 225 mg at Weeks 4 and 8), or placebo. Post hoc analyses evaluated the proportion of patients who reverted from CM to EM, defined as either a reduction to an average of <15 headache days per month during the 3‐month treatment period or a reduction to <15 headache days per month in all 3 months of the treatment period. RESULTS: This analysis included data from 1088 CM patients (quarterly, n = 366; monthly, n = 365; placebo, n = 357). More fremanezumab‐treated patients with CM reverted to EM using either the monthly average number of headache days criteria for reversion (quarterly: 50.5% [185/366], P = .108; monthly: 53.7% [196/365], P = .012; vs placebo: 44.5% [159/357]) or the monthly headache day count at Months 1, 2, and 3 criteria for reversion (quarterly: 31.2% [114/366], P = .008; monthly: 33.7% [123/365], P = .001; vs placebo: 22.4% [80/357]). Patients with CM who reported previous topiramate or onabotulinumtoxinA use, concomitant preventive medication use, or medication overuse were less likely to revert to EM. CONCLUSIONS: Fremanezumab may offer the benefit of reversion from CM to EM, based on a reduction in the number of headache days over 3 months of treatment.
format Online
Article
Text
id pubmed-7756262
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-77562622020-12-28 Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study Lipton, Richard B. Cohen, Joshua M. Bibeau, Kristen Galic, Maja Seminerio, Michael J. Ramirez Campos, Verena Halker Singh, Rashmi B. Ailani, Jessica Headache Research Submissions BACKGROUND: Migraine preventive medications are used to reduce headache frequency, severity, and duration. In patients with chronic migraine (CM), reversion to episodic migraine (EM) is an important treatment goal. OBJECTIVE: To evaluate the effect of fremanezumab on the rate of reversion from CM to EM. METHODS: This phase 3, randomized, double‐blind, placebo‐controlled, parallel‐group trial included a 28‐day pretreatment period and a 3‐month treatment period. Patients with CM received subcutaneous fremanezumab quarterly (675 mg at baseline) or monthly (675 mg at baseline; 225 mg at Weeks 4 and 8), or placebo. Post hoc analyses evaluated the proportion of patients who reverted from CM to EM, defined as either a reduction to an average of <15 headache days per month during the 3‐month treatment period or a reduction to <15 headache days per month in all 3 months of the treatment period. RESULTS: This analysis included data from 1088 CM patients (quarterly, n = 366; monthly, n = 365; placebo, n = 357). More fremanezumab‐treated patients with CM reverted to EM using either the monthly average number of headache days criteria for reversion (quarterly: 50.5% [185/366], P = .108; monthly: 53.7% [196/365], P = .012; vs placebo: 44.5% [159/357]) or the monthly headache day count at Months 1, 2, and 3 criteria for reversion (quarterly: 31.2% [114/366], P = .008; monthly: 33.7% [123/365], P = .001; vs placebo: 22.4% [80/357]). Patients with CM who reported previous topiramate or onabotulinumtoxinA use, concomitant preventive medication use, or medication overuse were less likely to revert to EM. CONCLUSIONS: Fremanezumab may offer the benefit of reversion from CM to EM, based on a reduction in the number of headache days over 3 months of treatment. John Wiley and Sons Inc. 2020-11-11 2020 /pmc/articles/PMC7756262/ /pubmed/33179323 http://dx.doi.org/10.1111/head.13997 Text en © 2020 The Authors. Headache: The Journal of Head and Face Pain published by Wiley Periodicals LLC on behalf of American Headache Society This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research Submissions
Lipton, Richard B.
Cohen, Joshua M.
Bibeau, Kristen
Galic, Maja
Seminerio, Michael J.
Ramirez Campos, Verena
Halker Singh, Rashmi B.
Ailani, Jessica
Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study
title Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study
title_full Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study
title_fullStr Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study
title_full_unstemmed Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study
title_short Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study
title_sort reversion from chronic migraine to episodic migraine in patients treated with fremanezumab: post hoc analysis from halo cm study
topic Research Submissions
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756262/
https://www.ncbi.nlm.nih.gov/pubmed/33179323
http://dx.doi.org/10.1111/head.13997
work_keys_str_mv AT liptonrichardb reversionfromchronicmigrainetoepisodicmigraineinpatientstreatedwithfremanezumabposthocanalysisfromhalocmstudy
AT cohenjoshuam reversionfromchronicmigrainetoepisodicmigraineinpatientstreatedwithfremanezumabposthocanalysisfromhalocmstudy
AT bibeaukristen reversionfromchronicmigrainetoepisodicmigraineinpatientstreatedwithfremanezumabposthocanalysisfromhalocmstudy
AT galicmaja reversionfromchronicmigrainetoepisodicmigraineinpatientstreatedwithfremanezumabposthocanalysisfromhalocmstudy
AT semineriomichaelj reversionfromchronicmigrainetoepisodicmigraineinpatientstreatedwithfremanezumabposthocanalysisfromhalocmstudy
AT ramirezcamposverena reversionfromchronicmigrainetoepisodicmigraineinpatientstreatedwithfremanezumabposthocanalysisfromhalocmstudy
AT halkersinghrashmib reversionfromchronicmigrainetoepisodicmigraineinpatientstreatedwithfremanezumabposthocanalysisfromhalocmstudy
AT ailanijessica reversionfromchronicmigrainetoepisodicmigraineinpatientstreatedwithfremanezumabposthocanalysisfromhalocmstudy